

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Modern Chinese Medicine Group Co., Ltd.

現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1643)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14.41(A) OF THE LISTING RULES AND DELAY IN DESPATCH OF CIRCULAR

Reference are made to the announcements of Modern Chinese Medicine Group Co., Ltd. (the “**Company**”) dated 19 January 2026 and 9 February 2026 in relation to the major transaction regarding the acquisition of sale shares (collectively the “**Announcements**”). Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless otherwise specified.

As set out in the Announcements, it was expected that the Company would despatch the Circular containing, among other matters, further information regarding the SPA and the transaction contemplated thereunder to the Shareholders for information purposes only in accordance with Rule 14.41(a) of the Listing Rules on or before 9 February 2026.

As additional time is required for finalising certain information for inclusion in the Circular, including the consolidated audited report of the Target Group for the three years ended 31 December 2025, the Company has applied to the Stock Exchange for the Waiver from strict compliance with Rule 14.41(a) of the Listing Rules.

On 11 February 2026, the Stock Exchange granted the Waiver and the expected despatch date of the Circular has been extended to a date on or before 30 April 2026. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

By Order of the Board
Modern Chinese Medicine Group Co., Ltd.
Zhang Hongli
Executive Director

Hong Kong, 12 February 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive Directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.